<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Florbetaben F-18: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Florbetaben F-18: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Florbetaben F-18: Drug information</div><div class="clear"></div><div id="topicText">For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55859567"><span class="drugH1">Brand Names: US</span>
<ul>
<li>NeuraCeq</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871734"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>NeuraCeq</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F24129710"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F24181780"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Measure dose by a suitable radioactivity calibration system immediately prior to administration. Dose may vary depending on patient's body weight and image acquisition parameters.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="91a27208-9f72-4358-88f6-b5cfa94442b1">Brain imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Brain imaging:</b> IV: 8.1 mCi (300 MBq); maximum: 30 mcg mass dose</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990418"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There is no dosage adjustment provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987461"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There is no dosage adjustment provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F24181781"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F24673448"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Local: Pain at injection site (3%), erythema at injection site (2%), irritation at injection site (1%)</p></div>
<div class="block coi drugH1Div" id="F24129713"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed within the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to florbetaben F18, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F24181320"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Patients are exposed to some radiation during treatment; large cumulative amounts of radiation exposure may increase the risk of cancer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced staff: Images should only be interpreted by specially trained personnel.</p>
<p style="text-indent:-2em;margin-left:4em;">• Limitations: A positive scan does not establish a diagnosis of Alzheimer disease or other cognitive disorders. Safety and effectiveness have not been established for predicting the development of a neurological condition (eg, dementia) or monitoring responses to therapy. Image interpretation provides an estimate of the brain beta-amyloid plaque density; it does not determine clinical diagnosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Risk for misinterpretation and errors: Images should be interpreted independently of the patient's clinical information. The use of clinical information in the interpretation of images has not been evaluated and may lead to errors. Errors may also occur due to severe brain atrophy and image distortion. Scan results are indicative of the brain neuritic amyloid plaque content only at the time of imaging. A negative scan result does not preclude the development of brain amyloid in the future.</p></div>
<div class="block foc drugH1Div" id="F55859568"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NeuraCeq: 1.4-135 MCI/ML (1 ea) [contains alcohol, usp, polyethylene glycol (macrogol)]</p></div>
<div class="block geq drugH1Div" id="F53040769"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55937462"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (NeuraCeq Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.4-135 mci/mL (per each): $3,360.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871735"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NeuraCeq: 1.4-135 MCI/ML (30 mL) [contains alcohol, usp]</p></div>
<div class="block adm drugH1Div" id="F24181843"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Administer as a single slow intravenous bolus (6 seconds/mL) in a total volume of 10 mL or less; do not dilute. Following injection, flush with NS to ensure full delivery of dose. Initiate 15 to 20 minute PET image 45 to 130 minutes after injection. Patient should remain supine with brain centered in the PET scanner field of view.</p>
<p style="text-indent:-2em;margin-left:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal. Waterproof gloves should be worn and effective shielding should be used during handling and administration.</p></div>
<div class="block use drugH1Div" id="F24129712"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Brain imaging:</b> For positron emission tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer disease and other causes of cognitive decline.</p></div>
<div class="block rep_considerations drugH1Div" id="F53559906"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pregnancy status should be evaluated prior to use in women of reproductive potential (Parker 2010).</p></div>
<div class="block pri drugH1Div" id="F24180900"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">All radiopharmaceuticals have the potential to cause fetal harm. Florbetaben F18 can be detected by radiation dosimetry in the uterus and ovary following injection.</p></div>
<div class="block brc drugH1Div" id="F24180902"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if florbetaben 18 is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed following imaging should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. The manufacturer recommends patients pump and discard breast milk for 24 hours after administration to minimize potential infant exposure via breast milk. F18 can be detected by radiation dosimetry in breast tissue. Elective diagnostic procedures should be delayed until breastfeeding has stopped (Parker 2010).</p></div>
<div class="block pha drugH1Div" id="F24181324"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Following IV administration, florbetaben F18 crosses the blood brain barrier and binds to β-amyloid plaques in the brain. The F18 isotope produces a positron signal that is detected by a PET scanner.</p></div>
<div class="block phk drugH1Div" id="F24181326"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: ~6% of the total dose distributed to the brain 10 minutes postadministration</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 98.5%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Predominantly catalyzed by CYP2J2 and CYP4F2</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~1 hour</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: Plasma concentrations declined ~75% and ~90% at 20 and 50 minutes, respectively</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine: ~30% (12 hours postadministration)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F24170919"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Neuraceq</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Neuraceq</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Neuraceq.1">
<a name="Neuraceq.1"></a>Neuraceq (florbetaben F 18 injection) [prescribing information]. Dulles, VA: Sofie Co; April 2023.</div>
</li>
<li>
<div class="reference">
                  NeuraCeq (florbetaben F 18 injection) [product monograph]. Lachine, Quebec, Canada; IsoLogic Innovative Radiopharmaceuticals; February 2017.</div>
</li>
<li>
<div class="reference">
                  Parker JA, Graham LS, Royal HD et al. Society of Nuclear Medicine Procedure Guideline for General Imaging. Version 6.0. 2010. http://www.snmmi.org/ClinicalPractice/content.aspx?ItemNumber=6414&amp;navItemNumber=10790#General. Accessed January 20, 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 94523 Version 76.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
